Back to Search Start Over

Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma

Authors :
Attilio Guarini
Maria Gomes da Silva
Yana Stepanishyna
Gilles Salles
Igor Aurer
Martina Manni
Franck Morschhauser
Silvia Montoto
Sandra Lockmer
María Dolores Caballero Barrigón
Harald Holte
Emanuele Zucca
Martine E.D. Chamuleau
Sara Galimberti
Marielle J. Wondergem
Laura Magnano
Sara Alonso-Álvarez
Clémentine Sarkozy
Miguel Alcoceba
Luigi Marcheselli
Massimo Federico
Hematology
CCA - Cancer Treatment and quality of life
Source :
Alonso-Álvarez, S, Manni, M, Montoto, S, Sarkozy, C, Morschhauser, F, Wondergem, M J, Guarini, A, Magnano, L, Alcoceba, M, Chamuleau, M, Galimberti, S, Gomes da Silva, M, Holte, H, Zucca, E, Lockmer, S, Aurer, I, Marcheselli, L, Stepanishyna, Y, Caballero Barrigón, M D, Salles, G & Federico, M 2021, ' Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma ', European Journal of Cancer, vol. 157, pp. 132-139 . https://doi.org/10.1016/j.ejca.2021.08.005, European Journal of Cancer, 157, 132-139. Pergamon
Publication Year :
2021

Abstract

Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical course from that of FL that responds to front-line treatments. In addition to having poor responses to salvage therapies, it seems that patients with PREF are at increased risk of histological transformation (HT). The Aristotle consortium presented the opportunity of investigating the risk of HT in a very large series of cases. Thus, we investigated the risk of HT in patients with PREF FL compared with that of responding patients or in stable disease and ultimately their outcome. Methods: Six thousand three hundred thirty-nine patients from the Aristotle database were included in the analysis. These patients had a histologically confirmed grade 1, 2 or 3a FL diagnosed between 1997 and 2013. The primary end-points were the cumulative incidence (CI) of HT at the first progression or relapse and the survival after transformation. Findings.: The 5-year CI of HT among patients with PREF was 34% (95% confidence interval (CI): 27–43), whilst it was 7.1% (95% CI: 6.0–8.5) in the group of patients with partial response (PR) or stable disease (SD) (PR + SD) and 3.5% (95% CI: 3.0–4.2) in the group of patients achieving complete response (CR). The 5-year survival after relapse (SAR) was 33% (95% CI: 28–39) for the PREF group, 57% (95% CI 54–61) in patients with PR, 51% (95% CI 43–58) in the SD group after first-line therapy and 63% (95% CI: 66–72) in patients with CR after initial treatment (p-value

Details

Language :
English
ISSN :
09598049
Database :
OpenAIRE
Journal :
Alonso-Álvarez, S, Manni, M, Montoto, S, Sarkozy, C, Morschhauser, F, Wondergem, M J, Guarini, A, Magnano, L, Alcoceba, M, Chamuleau, M, Galimberti, S, Gomes da Silva, M, Holte, H, Zucca, E, Lockmer, S, Aurer, I, Marcheselli, L, Stepanishyna, Y, Caballero Barrigón, M D, Salles, G & Federico, M 2021, ' Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma ', European Journal of Cancer, vol. 157, pp. 132-139 . https://doi.org/10.1016/j.ejca.2021.08.005, European Journal of Cancer, 157, 132-139. Pergamon
Accession number :
edsair.doi.dedup.....a667e202072aae0de08517a7589f6531
Full Text :
https://doi.org/10.1016/j.ejca.2021.08.005